Latest news with #multiple_myeloma
Medical News Today
13 hours ago
- Health
- Medical News Today
What happens if CAR T-cell therapy fails to treat multiple myeloma?
Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy. Immunotherapy helps the body's immune system locate and attack the cancer Food and Drug Administration (FDA) has approved two CAR T-cell therapies to treat multiple myeloma (MM): Idecabtagene vicleucel (ide-cel, Abecma) and Ciltacabtagene autoleucel (cilta-cel, Carvykti). These target a protein called BCMA, which is found on myeloma cells. CAR T-cell therapy has shown great success in treating MM that has not responded to other treatments or has come back. However, this treatment may not work for everybody. Most CAR T-cell therapy failures occur within 6 months of to a 2022 article, there is no agreed-upon standard of care if CAR T-cell therapy fails. Instead, a person will work with their healthcare team to come up with a different treatment plan. In some cases, they may suggest a second round of CAR T-cell the most commonly used therapies after CAR T-cell failure include:chemotherapy with the drug lenalidomidetargeted therapychemoimmunotherapybispecific antibodieslocalized radiation therapyFinding out that a treatment option has not worked can be challenging to manage. A person may benefit from seeking support from loved ones, support groups, mental health professionals, and a member of their healthcare team. A mental health professional can help a person manage the psychological aspects of living with a medical condition, and a healthcare professional will be able to answer any questions a person may undergoing treatment for MM can find support and resources at the following organizations:American Cancer SocietyLeukemia & Lymphoma SocietyCancerCareMultiple Myeloma Research FoundationInternational Myeloma FoundationLearn moreWhat to do next when multiple myeloma treatment stops workingCan multiple myeloma be cured?Multiple myeloma: Treatment and moreTypes of maintenance therapy for multiple myelomaWhat are some risks of stopping treatment for multiple myeloma?
Medscape
a day ago
- Health
- Medscape
Clinical Advances in Multiple Myeloma From ASCO 2025
The coming of age of chimeric antigen receptor (CAR) T-cell therapy, the selection of postinduction therapy on the basis of residual disease activity, and a novel drug delivery system are among the developments in multiple myeloma (MM) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Dr Joseph Mikhael, from City of Hope Cancer Center in Phoenix, Arizona, opens with long-term follow-up data from the CARTITUDE-1 trial of ciltacabtagene autoleucel CAR T-cell therapy in heavily pretreated relapsed/refractory MM. One third of patients remained progression free for 5 or more years following a single infusion, offering hope of a cure. Next, he discusses the MIDAS trial of newly diagnosed MM, in which the treatment choice was driven by residual disease activity after induction therapy. The results indicated that autologous stem cell transplant may not be beneficial in patients with no residual disease activity and could potentially be avoided. Dr Mikhael then turns to follow-up from PERSEUS, again in newly diagnosed disease. The data showed daratumumab to be a key component of both induction therapy when combined with bortezomib, lenalidomide, dexamethasone, and maintenance therapy in combination with lenalidomide. In closing, he discusses a German trial that underlined the importance of aggressive treatment in high-risk newly diagnosed MM as well as an analysis of an on-body delivery system for subcutaneous isatuximab that met with patient satisfaction.
